T2 Biosystems to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
November 11 2016 - 6:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John
McDonough, president and chief executive officer, and Shawn
Lynch, chief financial officer, are scheduled to attend and present
at the Canaccord Genuity Medical Technologies & Diagnostics
Forum on Thursday, November 17, 2016, at 2:00 p.m. ET in New
York City.
A live, listen-only webcast of the presentation may be accessed
by visiting the Investors/Events & Presentations section of the
Company’s website at www.t2biosystems.com. A replay of the
webcast will be available shortly after the conclusion of the
presentation and will be archived on the Company's website for 30
days.
About T2 BiosystemsT2 Biosystems is
focused on developing innovative diagnostic products to improve
patient health. With two FDA-cleared products targeting sepsis and
a range of additional products in development, T2 Biosystems is an
emerging leader in the field of in vitro diagnostics. The Company
is utilizing its proprietary T2 Magnetic Resonance platform, or
T2MR®, to develop a broad set of applications aimed at lowering
mortality rates, improving patient outcomes and reducing the cost
of healthcare by helping medical professionals make targeted
treatment decisions earlier. T2MR enables the fast and sensitive
detection of pathogens, biomarkers and other abnormalities in a
variety of unpurified patient sample types, including whole blood,
eliminating the time-consuming sample prep required in current
methods. For more information, please visit
www.t2biosystems.com.
Media Contact:
Susan Heins,
Pure Communications
susan@purecommunicationsinc.com
864-286-9597
Investor Contact:
Matt Clawson,
Pure Communications
matt@purecommunicationsinc.com
949-370-8500
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024